Hemp cannabidiol (CBD) products maker CV Sciences, Inc. CVSI has signed a distribution agreement with health and nutrition-related products behemoth GNC.
Beginning in early 2022, consumers will be able to purchase CVSI’s ingestible products under the +PlusCBD brand in 770 GNC locations. The initial product lineup will include:
- Extra Strength Formula: Cherry Mango Gummies – 10mg CBD per gummy, 30 count
- Extra Strength Formula: Softgels – 15mg per serving, 30 count
- Extra Strength: Peppermint Liquid – 10mg per serving
- Raspberry Sleep Gummies: 10mg per gummy with Magnolia, Lemon Balm & Melatonin, 30 count
- Strawberry Lemonade Calm Gummies: 10mg per gummy with L-Theanine & 5-HTP, 30 count
“We are thrilled to partner with GNC, a leading global health and wellness brand, and view this agreement as a major milestone in our distribution expansion strategy as well as a strong testament to the safety and efficacy of CV Sciences’ portfolio of high-quality products,” said Joseph Dowling, CEO of CV Sciences. “This agreement is also a positive reflection of the favorable regulatory momentum that is starting to build following the recent passage of AB 45 in California, which should serve as a framework for responsible CBD legislation in other states and eventually at the federal level.”
Más contenido sobre cannabis en Español en El Planteo.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.